SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice
Our results suggest that the combination of SGLT2i with GLP-1RA is superior in cardiorenal protection in DKD than the drugs administered alone on top of RAS blockade.
Authors
- Sheila Bermejo (ORCID: https://orcid.org/0000-0002-3611-4830)
- Ander Vergara (ORCID: https://orcid.org/0000-0003-1926-0147)
- Aku Enam Motto (ORCID: https://orcid.org/0000-0002-1360-2989)
- A. Narváez (ORCID: https://orcid.org/0000-0001-5227-6867)
- Irene Martínez-Díaz (ORCID: https://orcid.org/0000-0001-5849-7900)
- Francisco Gonçalves (ORCID: https://orcid.org/0000-0003-1495-9362)
- María José Soler (ORCID: https://orcid.org/0000-0003-3621-0766)
- Juan León-Román
- Roser Ferrer (ORCID: https://orcid.org/0000-0002-8925-3172)
- Carmen Llorens-Cebrià (ORCID: https://orcid.org/0000-0002-3611-1816)
- Conxita Jacobs-Cachá (ORCID: https://orcid.org/0000-0003-2518-7847)
- Nerea Martos-Guillamí
- Jordi Vilardell-Vilà
- Maria Magdalena Garcias-Ramis
- Estibaliz Allo-Urzainqui
- Vicent Muñoz
Institutions
- Instituto de Salud Carlos III (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
- University of Lomé (TG)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.3389/fphar.2024.1415879
- Citations
- 8
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.86
Funders
- Fundació la Marató de TV3
- Instituto de Salud Carlos III